Pharmaceutical Companies in Iraq
A comprehensive guide to the pharmaceutical industry in Iraq — a large population market (44.5M, second-largest Arab state) with $2.8B market growing at 8.5%. Post-conflict reconstruction is driving investment; KIMADIA dominates government procurement; dual market (federal + KRG); ~80% imports; $63/capita shows massive growth potential.
Last updated: February 2026 · Sources: MOH, KIMADIA, BioNixus MEA, company and industry reports
Cite this guide
BioNixus. "Pharmaceutical Companies in Iraq: Complete Industry Guide 2026." BioNixus Healthcare Market Research, Feb. 2026, https://www.bionixus.com/pharmaceutical-companies-iraq.
Licensed under CC BY 4.0 — free to share and adapt with attribution.
$2.8B
Pharmaceutical market value
8.5%
Year-over-year growth
44.5M
Population
$63
Pharma spending per capita
Iraq Pharmaceutical Market Overview
Iraq's pharmaceutical market is a large population market — 44.5 million people (second-largest Arab state) — valued at approximately US$2.8 billion, growing at 8.5% year-over-year. Per-capita pharmaceutical spending of $63 indicates massive growth potential as healthcare access and insurance coverage expand.
Post-conflict healthcare reconstruction is driving investment, with $5B+ invested in healthcare. KIMADIA (State Company for Marketing Drugs & Medical Appliances) under the MOH dominates government procurement in federal Iraq. The market is dual: federal Iraq and the Kurdistan Region (KRG) operate separate procurement systems. Approximately 80% of pharmaceuticals are imported; local manufacturing is led by SDI (State Company for Drug Industries, Samarra) and a small number of private and joint-venture manufacturers.
Chronic disease burden (diabetes, cardiovascular) and one of the youngest demographics in the region drive sustained demand. NGO and international health partnerships play a significant role in supply and access. For broader regional context, see our MENA Pharmaceutical Market Data 2026 and GCC Pharmaceutical Market Access Guide.
Top Pharmaceutical Companies in Iraq
The following table lists the major pharmaceutical companies operating in Iraq — including local manufacturers, multinational corporation offices, regional players, and leading distributors.
| Company | HQ |
|---|---|
| SDI (State Company for Drug Industries) | Samarra, Iraq |
| Iraqi-Egyptian Company for Pharmaceutical Industries | Iraq |
| Pioneer Industries Company | Iraq |
| Dar Al Dawa - Iraq | Erbil, Iraq |
| Modern Drug Industries (MDI) | Iraq |
| Pfizer | USA |
| Novartis | Switzerland |
| Roche | Switzerland |
| Sanofi | France |
| AstraZeneca | UK / Sweden |
| GSK (GlaxoSmithKline) | UK |
| Novo Nordisk | Denmark |
| Julphar | UAE |
| Hikma Pharmaceuticals | Jordan / UK |
| Pharma International | Jordan |
| SPIMACO | Saudi Arabia |
| Ibn Hayyan Pharma | Iraq |
| Dijla Pharma | Baghdad, Iraq |
| Al Masar Pharma | Iraq |
List of Pharmaceutical Companies in Iraq by Category
Iraq pharmaceutical companies span local manufacturers (state-owned and private), multinational corporation offices, regional players, and major distributors.
Local Manufacturers
Local manufacturing is limited; ~80% of the market is imported. Key players include SDI (State Company for Drug Industries, Samarra — largest state-owned), Iraqi-Egyptian Company for Pharmaceutical Industries (joint venture), Pioneer Industries Company (private generics), Dar Al Dawa - Iraq (Jordanian JV, Erbil-based), and Modern Drug Industries (MDI).
- ✓ SDI (State Company for Drug Industries)
- ✓ Iraqi-Egyptian Company for Pharmaceutical Industries
- ✓ Pioneer Industries Company
- ✓ Dar Al Dawa - Iraq
- ✓ Modern Drug Industries (MDI)
Multinational Pharma Offices
Major global pharmaceutical companies maintain presence in Iraq. MNCs supply innovator and specialty drugs through KIMADIA tenders and private channels.
- ✓ Pfizer
- ✓ Novartis
- ✓ Roche
- ✓ Sanofi
- ✓ AstraZeneca
- ✓ GSK (GlaxoSmithKline)
- ✓ Novo Nordisk
Regional Pharma Companies
Regional players from UAE (Julphar), Jordan/UK (Hikma — strong Iraq presence), Jordan (Pharma International), and Saudi (SPIMACO) are active in the Iraqi market.
- ✓ Julphar
- ✓ Hikma Pharmaceuticals
- ✓ Pharma International
- ✓ SPIMACO
Distributors
Major distributors include Ibn Hayyan Pharma, Dijla Pharma (Baghdad-based), and Al Masar Pharma. Private pharmacies (30,000+) serve the private channel.
- ✓ Ibn Hayyan Pharma
- ✓ Dijla Pharma
- ✓ Al Masar Pharma
Pharma Companies in Iraq: KIMADIA Regulatory Landscape
The Ministry of Health (MOH) and KIMADIA (State Company for Marketing Drugs & Medical Appliances) oversee pharmaceutical registration, pricing, and government procurement in federal Iraq.
Regulatory Authority
The MOH and KIMADIA (State Company for Marketing Drugs & Medical Appliances) oversee drug registration, government procurement, and distribution in federal Iraq. Pricing is government-controlled (KIMADIA tender pricing). The Kurdistan Region (KRG) has a separate procurement system.
Registration Timeline
12–24 months
Renewal Period
5 years
Pricing Model
Government-controlled (KIMADIA tender pricing)
Key Registration Requirements
- ✓Submission via MOH/KIMADIA processes
- ✓GMP and quality documentation
- ✓Arabic labelling where required
- ✓Tender participation for government channel
- Separate KRG pathway for Kurdistan Region market
Dual Market: Federal Iraq & KRG
Companies targeting the full Iraqi market must engage both federal Iraq (MOH/KIMADIA) and the Kurdistan Region (KRG), which has a separate healthcare and procurement system. For GCC and broader MENA registration context, see our GCC Pharmaceutical Market Access Guide.
Drug Distribution Channels in Iraq
Iraq's pharmaceutical distribution is split between government procurement (KIMADIA-dominated) and the private channel (pharmacies and distributors).
Government Channel (KIMADIA)
KIMADIA dominates government procurement in federal Iraq. Tender pricing is government-controlled. Public hospitals and MOH facilities are supplied through this channel.
- ► KIMADIA tender system
- ► MOH and public healthcare facilities
- ► Government-controlled pricing
Private Channel & KRG
Private pharmacies (30,000+) serve the private channel. Major distributors include Ibn Hayyan Pharma, Dijla Pharma (Baghdad), and Al Masar Pharma. KRG has a separate procurement system in the Kurdistan Region.
- ► 30,000+ private pharmacies
- ► Major distributors (Ibn Hayyan, Dijla, Al Masar)
- ► KRG separate procurement in Kurdistan
- ► Growing insurance coverage
Iraqi Pharmaceutical Market Growth Drivers
Post-conflict reconstruction, demographics, and healthcare investment are driving growth in Iraq's pharmaceutical sector.
Post-Conflict Healthcare Reconstruction
Over $5B+ invested in healthcare reconstruction, creating sustained demand for medicines, hospital supplies, and infrastructure. International and NGO partnerships support access and supply.
Population & Demographics
44.5 million population (second-largest Arab state) with one of the youngest demographics in the region, driving long-term market expansion and per-capita growth potential ($63/capita).
Kurdistan Region (KRG) Market
KRG operates a separate healthcare and procurement system, offering a distinct market segment and access pathway for companies.
Growing Insurance Coverage
Expanding insurance coverage is increasing private-sector utilisation and creating more predictable reimbursement dynamics.
Chronic Disease Burden
Diabetes, cardiovascular disease, and other chronic conditions drive sustained demand for metabolic, cardiovascular, and specialty therapies.
NGO & International Partnerships
NGO and international health partnerships play a significant role in supply, access, and capacity building in the Iraqi market.
How BioNixus Supports Pharma Companies in Iraq
BioNixus supports pharma, biotech, and medtech companies with market intelligence and strategy for the Iraqi market:
Market Entry & Regulatory Strategy
KIMADIA and KRG pathway analysis, tender strategy, local partner identification, and dual federal-KRG market access planning.
Competitive Intelligence
Monitoring of competitor presence, tender outcomes, distributor landscape, and market share across federal Iraq and KRG.
Stakeholder & KOL Mapping
Physician and payer mapping across MOH, KRG, and private sector; NGO and international partnership landscape.
Market Sizing & Demand Assessment
Market sizing, therapeutic area demand, and growth drivers for the $2.8B Iraqi pharma market and KRG segment.
Frequently Asked Questions
How many pharmaceutical companies operate in Iraq?
Iraq has approximately 18 major pharmaceutical companies including local manufacturers (e.g. SDI, Iraqi-Egyptian Company, Pioneer Industries, Dar Al Dawa - Iraq, MDI), MNC offices (Pfizer, Novartis, Roche, Sanofi, AstraZeneca, GSK, Novo Nordisk), regional players (Julphar, Hikma, Pharma International, SPIMACO), and major distributors (Ibn Hayyan Pharma, Dijla Pharma, Al Masar Pharma). The market is valued at $2.8 billion with ~80% import dependency.
What is the size of Iraq's pharmaceutical market?
Iraq's pharmaceutical market is valued at approximately US$2.8 billion, growing at 8.5% year-over-year. With a population of 44.5 million (second-largest Arab state) and per-capita pharmaceutical spending of $63, the market has massive growth potential. Post-conflict healthcare reconstruction ($5B+ invested) and chronic disease burden are key drivers.
What is KIMADIA's role in Iraq's pharmaceutical market?
KIMADIA (State Company for Marketing Drugs & Medical Appliances) under the Ministry of Health (MOH) dominates government procurement in federal Iraq. It manages drug registration, tender pricing, and distribution to public healthcare facilities. Pricing is government-controlled via KIMADIA tender pricing. Private pharmacies (30,000+) serve the private channel.
How does the Kurdistan Region (KRG) market differ?
The Kurdistan Region has a separate healthcare market and procurement system from federal Iraq. Companies targeting the full Iraqi market must engage both federal (MOH/KIMADIA) and KRG systems. KRG represents a distinct access pathway and formulary environment.
What is the status of local pharmaceutical manufacturing in Iraq?
Local manufacturing exists but is limited; approximately 80% of pharmaceuticals are imported. Key local manufacturers include SDI (State Company for Drug Industries, Samarra — largest state-owned), Iraqi-Egyptian Company for Pharmaceutical Industries (joint venture), Pioneer Industries Company, Dar Al Dawa - Iraq (Jordanian JV, Erbil-based), and Modern Drug Industries (MDI). Post-conflict reconstruction is driving investment in healthcare infrastructure.
What are the main market entry challenges in Iraq?
Market entry challenges include navigating dual federal and KRG regulatory/procurement systems, KIMADIA-dominated government tenders, 12–24 month registration timelines with 5-year renewal, government-controlled pricing, and post-conflict operational considerations. Local or regional partners and understanding NGO and international health partnerships can support market access.
Data Sources & Methodology
This guide aggregates publicly available information from:
- MOH and KIMADIA public information
- BioNixus Middle East & Africa market reports
- Company and industry reports
- BioNixus proprietary research
For customised market intelligence on Iraq, contact our team.
Need Market Intelligence on Iraq?
BioNixus delivers custom pharmaceutical market research for Iraq and the wider MENA region — market entry strategy, KIMADIA/KRG pathways, competitive intelligence, and stakeholder mapping.